EU GMP Guide Annex 11 “Computerised Systems” Edwin Lindsey Understudy: Neil Fraser.

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Radiopharmaceutical Production
Radiopharmaceutical Production
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
EQUIPMENT VALIDATION.
Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.
GMP Document and Record Retention
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.
1 Certification Chapter 14, Storey. 2 Topics  What is certification?  Various forms of certification  The process of system certification (the planning.
Main Requirements on Different Stages of the Licensing Process for New Nuclear Facilities Module 4.7 Commissioning Geoff Vaughan University of Central.
Supplementary Training Modules on Good Manufacturing Practice
Examine Quality Assurance/Quality Control Documentation
©Ian Sommerville 2004Software Engineering, 7th edition. Chapter 27 Slide 1 Quality Management 1.
ISO 9000 Certification ISO 9001 and ISO
Good Manufacturing Practices for Blood Establishments
Personnel Basic Principles of GMP Workshop on
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
QC | Slide 1 of 16 June 2006 Good Practices for Quality Control Laboratories P art 4: Inspecting the laboratory Supplementary Training Modules on Good.
Computer Systems & Software
Validation of Computerized Laboratory Systems
Welcome ISO9001:2000 Foundation Workshop.
Module 1, Part 1: Introduction and The VMP Slide 1 of 22 © WHO – EDM Validation Supplementary Training Modules on Good Manufacturing Practices.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
Bodil Mose Pedersen, DHI Status for implementering af ”Quality Manual”
DRAFT Richard Chandler-Mant – R Consultant The Challenges of Validating R Managing R in a Commercial Environment.
World Health Organization
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
MethodGXP The Solution for the Confusion.
Basic Principles of GMP
Designing Smart Cities Conference University of Strathclyde, Glasgow 31 st March 2015 “Regulating Smart Cities: Policing & Privacy” Paul Mackie Chief Executive.
FDA Docket No. 2004N-0133 Themes for Renewal of 21 CFR Part 11 Rule & Guidance by Dr. Teri Stokes, GXP International
Important acronyms AO = authorizing official ISO = information system owner CA = certification agent.
Important informations
ISO / IEC : 2012 Conformity assessment – Requirements for the operation of various types of bodies performing inspection.
ISO 9001:2008 to ISO 9001:2015 Summary of Changes
Good Practices in Production and Quality Control Related Guidelines
Workshop on Implementing Audit Quality Practices Working Group on Audit Manuals and Methods March 2006 Vilnius (Lithuania) Hungarian Experiences.
Validation | Slide 1 of 27 August 2006 Validation Supplementary Training Modules on Good Manufacturing Practice WHO Technical Report Series, No. 937, 2006.
International Security Management Standards. BS ISO/IEC 17799:2005 BS ISO/IEC 27001:2005 First edition – ISO/IEC 17799:2000 Second edition ISO/IEC 17799:2005.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Chapter 8 Auditing in an E-commerce Environment
Module 12 - part 1Slide 1 of 15 WHO - EDM Basic Principles of GMP Documentation Part 1 Part One, 14.
Module 14Slide 1 of 23 WHO - EDM Basic Principles of GMP Active Pharmaceutical Ingredients Part Three, 18.
Pharmaceutical Quality Control & current Good Manufacturing Practice
The NIST Special Publications for Security Management By: Waylon Coulter.
DOCUMENTATION ISO/IEC 17025:2005 Documentation.
Laboratory equipment Dr. W. Huisman Cairo, November 21th 2012.
Quality Control significance in pharmaceutical industry
Important acronyms AO = authorizing official ISO = information system owner CA = certification agent.
WHO - PSM Basic Principles of GMP Documentation - Part 1 Workshop on GMP and Quality Assurance of HIV products Shanghai, China 28 Feb - 4 March 2005 Maija.
Introduction for the Implementation of Software Configuration Management I thought I knew it all !
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
World Health Organization
ISO/IEC
Pharmaceutical Quality Control & current Good Manufacturing Practice
MHRA GMP Inspection Deficiency Data Trend 2016
Good Practices (GMP, GLP, GCP), inspections including Pharmacopoeias
HIGHLIGHTING THE KEY CHANGES
Outcome TFCS-11// February Washington DC
GMP Inspection Process
בקרה תוך שימוש ב 21CFR Part 11 / אילן שעיה סמארט לוג'יק
Interview Task 1.
Overview of the recommendations on software updates
Software Reviews.
Computer System Validation
Radiopharmaceutical Production
Radiopharmaceutical Production
Presentation transcript:

EU GMP Guide Annex 11 “Computerised Systems” Edwin Lindsey Understudy: Neil Fraser

This man is an idiot

OQ PQ Project preparation Go Live and Monitoring Project progress Validation progress Validation Master Plan Vendor Audit  DQ Protocol  User Requirement Specification  IQ Protocol  OQ Protocol  OQ Tests  OQ Report  Installation  IQ Report Documentation in place Go Live  PQ Protocol  PQ testing Validation Summary Report  PQ Report DQ IQ Qualification Stages (IQ/OQ/PQ) Change Control Risk Management

What’s it all about? Commission Directive 2003/94/EC, of 8 October 2003, laying down the “ principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use ”2003/94/EC Commission Directive 91/412/EEC of 23 July 1991 laying down the principles and guidelines of good manufacturing practice for veterinary medicinal products.91/412/EEC

Part I - Basic Requirements for Medicinal Products Chapter 1Quality Management (last revision February 2008) Chapter 2Personnel Chapter 3Premise and Equipment Chapter 4Documentation Chapter 5Production Chapter 6Quality Control (revision October 2005) Chapter 7Contract Manufacture and Analysis Chapter 8Complaints and Product Recall (revision December 2005) Chapter 9Self Inspection

Annexes Annex 1Manufacture of Sterile Medicinal Products (February 2008) Annex 2Manufacture of Biological Medicinal Products for Human Use Annex 3Manufacture of RadioPharmaceuticals (March 2009) Annex 4Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products Annex 5Manufacture of Immunological Veterinary Medicinal Products Annex 6Manufacture of Medicinal Gases Annex 7Manufacture of Herbal Medicinal Products (September 2009) Annex 8Sampling of Starting and Packaging Materials Annex 9Manufacture of Liquids, Creams and Ointments Annex 10Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation Annex 11Computerised Systems Annex 12Use of Ionising Radiation in the Manufacture of Medicinal Products Annex 13Manufacture of Investigational Medicinal Products Annex 14Manufacture of Products derived from Human Blood or Human Plasma Annex 15Qualification and validation (July 2001) Annex 16Certification by a Qualified person and Batch Release (July 2001) Annex 17Parametric Release (July 2001) Annex 18Good manufacturing practice for active pharmaceutical ingredients Annex 19 Reference and Retention Samples (December 2005) Annex 20 Quality Risk Management (February 2008)

Annexes Annex 1Manufacture of Sterile Medicinal Products (February 2008) Annex 2Manufacture of Biological Medicinal Products for Human Use Annex 3Manufacture of RadioPharmaceuticals (March 2009) Annex 4Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products Annex 5Manufacture of Immunological Veterinary Medicinal Products Annex 6Manufacture of Medicinal Gases Annex 7Manufacture of Herbal Medicinal Products (September 2009) Annex 8Sampling of Starting and Packaging Materials Annex 9Manufacture of Liquids, Creams and Ointments Annex 10Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation Annex 11Computerised Systems Annex 12Use of Ionising Radiation in the Manufacture of Medicinal Products Annex 13Manufacture of Investigational Medicinal Products Annex 14Manufacture of Products derived from Human Blood or Human Plasma Annex 15Qualification and validation (July 2001) Annex 16Certification by a Qualified person and Batch Release (July 2001) Annex 17Parametric Release (July 2001) Annex 18Good manufacturing practice for active pharmaceutical ingredients Annex 19 Reference and Retention Samples (December 2005) Annex 20 Quality Risk Management (February 2008)

What is Annex 11 Objective – –To ensure that when computerised systems replace manual systems, product quality does not decrease.

What is annex 11? Deals with: – –Inspection of computerised systems. Provides recommendations

Overview of Annex 11 Risk Management Risk Management Personnel Personnel Validation Validation System System Software Software Data Data User testing and the system's fitness for purpose User testing and the system's fitness for purpose Security Security Accuracy Checks Accuracy Checks Audit Trails Audit Trails Signatures Signatures Change control and configuration management Change control and configuration management Printouts Printouts Data Storage Data Storage Back Up; Migration; Archiving; Retrieval Back Up; Migration; Archiving; Retrieval Business Continuity Business Continuity Incident Management Incident Management Suppliers Suppliers Batch Release Batch Release

Overview of Annex 11 Here, the validation of the systems is meant to form the foundation of trust both for the licence holder and for the supervisory authority. Here, the validation of the systems is meant to form the foundation of trust both for the licence holder and for the supervisory authority. New role of risk management. New role of risk management.

Why Changing Newer initiatives in quality were not included Newer initiatives in quality were not included With greater experience in the field greater specificity could be included in the document With greater experience in the field greater specificity could be included in the document

Other Guidance/Standards used in the Change The draft standard includes the developments of the past years, it quotes in particular from: The draft standard includes the developments of the past years, it quotes in particular from: –PIC/s Guidance PII "Good practices for computerised systems in ‚GxP' regulated environments", –ISO "A code of practice for information security management“ –GAMP 5

Sources Annex 11: Annex 11: /eudralex/vol-4/pdfs-en/anx11en.pdf /eudralex/vol-4/pdfs-en/anx11en.pdf Chapter 4: Chapter 4: /eudralex/vol-4/pdfs-en/cap4en pdf /eudralex/vol-4/pdfs-en/cap4en pdf

What has changed The concept of risk assessment in the decision making process has been clearly introduced. The concept of risk assessment in the decision making process has been clearly introduced.

“Decisions on the extent of validation and data integrity controls should be based on a justified and documented risk assessment of the computerised system in respect to its impact on product quality and safety as well as data security and integrity.” “Decisions on the extent of validation and data integrity controls should be based on a justified and documented risk assessment of the computerised system in respect to its impact on product quality and safety as well as data security and integrity.”

OQ PQ Project preparation Go Live and Monitoring Project progress Validation progress Validation Master Plan Vendor Audit  DQ Protocol  User Requirement Specification  IQ Protocol  OQ Protocol  OQ Tests  OQ Report  Installation  IQ Report Documentation in place Go Live  PQ Protocol  PQ testing Validation Summary Report  PQ Report DQ IQ Qualification Stages (IQ/OQ/PQ) Change Control Risk Management

What has changed Inventory listings of systems with descriptions/ schematics. Inventory listings of systems with descriptions/ schematics. Introduce concept of ‘specifications’ for system and relationships. Introduce concept of ‘specifications’ for system and relationships. Design and development – new term and assessment measures for quality. Design and development – new term and assessment measures for quality.

What has changed Change and risk - controls and management. Change and risk - controls and management. Emphasise the intrinsic key differences between printed ‘audit trails’ and electronic ones. Emphasise the intrinsic key differences between printed ‘audit trails’ and electronic ones. Requirements for back up, archiving, migration and retrieval of data and records to be expanded considerably. Requirements for back up, archiving, migration and retrieval of data and records to be expanded considerably.

What has changed Term ‘business continuity’ to be introduced. Term ‘business continuity’ to be introduced. System failure section to be covered by new content – ‘Incident Management’, linking impact risk to corrective measures required. System failure section to be covered by new content – ‘Incident Management’, linking impact risk to corrective measures required. Outside agencies’ to be extended to embrace suppliers – other third parties and internal departments (where appropriate). Outside agencies’ to be extended to embrace suppliers – other third parties and internal departments (where appropriate).

What has changed Release certification – paper printouts and electronic system issues to be clarified. Release certification – paper printouts and electronic system issues to be clarified. New section on identity and electronic signature requirements New section on identity and electronic signature requirements Security controls – expand considerably (physical, procedural and electronic). Security controls – expand considerably (physical, procedural and electronic).

Areas to Consider Emphasis on risk based validation approach, Emphasis on risk based validation approach, Very strong emphasis on the inventory of systems including their validation status and risk rating Very strong emphasis on the inventory of systems including their validation status and risk rating Challenge testing evidence required (3.5) Challenge testing evidence required (3.5) Comprehensive periodic reviews must be performed, including security (3.6) Comprehensive periodic reviews must be performed, including security (3.6) Complete system specifications are needed (4.2) Complete system specifications are needed (4.2) Supplier audit reports/assessments must be available to the inspectors Supplier audit reports/assessments must be available to the inspectors Independent check of critical parameters is a requirement (9.2) Independent check of critical parameters is a requirement (9.2) Business Continuity must be tested (16.1) Business Continuity must be tested (16.1) Formal contract with suppliers including responsibility matrix (18.1) Formal contract with suppliers including responsibility matrix (18.1)

Areas to Consider The validation of databases : The validation of databases : –Provisions for data security –Recovery mechanisms –Performance tests

Areas to Consider Concerning hardware Concerning hardware –Site and purpose of the system –Risk classification for each system –Identification of the systems with impact on regulatory activities

Areas to Consider validation : validation : –User requirements –Periodic checks

Areas to Consider The following items must exist: The following items must exist: –The required system functions –Modules and their relationship –Interfaces and external connections –System limits –Hardware and software prerequisites

In Summary It also becomes clear that this new Annex 11 will again define terms of reference for the complete field of computerised systems in the Life Science industry. It also becomes clear that this new Annex 11 will again define terms of reference for the complete field of computerised systems in the Life Science industry.

In Summary Risk assessment is key to determining what is necessary– but ensure that risk aversion related to computer system development does not outweigh the benefits in accessing and using the data Risk assessment is key to determining what is necessary– but ensure that risk aversion related to computer system development does not outweigh the benefits in accessing and using the data

In Summary The updated annex 11 was out for consultation. (Review period ended 31 st October 2008) The updated annex 11 was out for consultation. (Review period ended 31 st October 2008) New version should be released early 2009 New version should be released early 2009

“I’ve not changed my style. My manager has just polished it up and brought some things that were in the background, to the foreground” Ricky Hatton, 2008

“I’ll be back. Don’t worry…….I’m sorry everybody” Ricky Hatton, 2008 Neil Fraser, 2008

Any Questions you can contact Edwin Lindsay at